Related Experiment Video
Updated: Apr 10, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Advanced prostate cancer: Every Voice Matters
Insights
Dr. Heather Payne is a leading clinical oncologist specializing in urological malignancies. She is dedicated to improving patient quality of life and advancing prostate cancer research and treatment through clinical studies and leadership roles.
Area of Science:
- Oncology
- Urology
- Clinical Research
Background:
- Dr. Heather Payne is a Consultant Clinical Oncologist at University College Hospital, London.
- She specializes in the management of urological malignancies, with extensive experience in clinical research.
Discussion:
- Dr. Payne is actively involved as a principal investigator in international and local multicenter studies.
- She focuses on enhancing patient quality of life and aiding treatment decision-making.
Key Insights:
- Her expertise includes urological cancer management and clinical trial leadership.
- She holds significant leadership positions in national prostate cancer initiatives.
Outlook:
- Dr. Payne's work contributes to advancing prostate cancer research and patient care.
- Her involvement in audits and advisory groups shapes future treatment strategies.
Abstract:
Heather Payne speaks to Gemma Westcott, Commissioning Editor: Heather Payne was appointed as a consultant in Clinical Oncology at University College Hospital (London, UK) in 1997. Following her training at St Mary's Hospital London Medical School and after qualifying, she spent time working in general medicine in both London and Haiti. Currently, she specializes in the management of urological malignancies, and is actively involved in clinical research as well as being the principal investigator in a number of international multicenter and local studies. She enjoys helping patients with quality of life and decision-making issues with regard to their treatment options. In addition, she is the chairman of the British Uro-oncology Group, and is a member of the Department of Health Prostate Cancer Advisory Group. Further to this, she is a trustee of the Prostate Cancer Research Centre and clinical lead for the National Prostate Cancer Audit.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:08A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
